Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
Recent studies indicate that interactions between leukemia cells and the bone marrow (BM) microenvironment promote leukemia cell survival and confer resistance to anti-leukemic drugs. There is evidence that BM microenvironment contains hypoxic areas that confer survival advantage to hematopoietic ce...
Main Authors: | Juliana Benito, Yuexi Shi, Barbara Szymanska, Hernan Carol, Ingrid Boehm, Hongbo Lu, Sergej Konoplev, Wendy Fang, Patrick A Zweidler-McKay, Dario Campana, Gautam Borthakur, Carlos Bueso-Ramos, Elizabeth Shpall, Deborah A Thomas, Craig T Jordan, Hagop Kantarjian, William R Wilson, Richard Lock, Michael Andreeff, Marina Konopleva |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3154919?pdf=render |
Similar Items
-
The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104
by: Annika eFoehrenbacher, et al.
Published: (2013-10-01) -
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
by: Yue Li, et al.
Published: (2021-07-01) -
The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
by: Yue Li, et al.
Published: (2021-04-01) -
From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
by: Yanming Wang, et al.
Published: (2022-01-01) -
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
by: William A. Denny
Published: (2022-02-01)